Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.

    Virtual Booth

    Contact Supplier

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Reports 4-Year Data From Blarcamesine Alzheimer Trial
    Anavex Reports 4-Year Data From Blarcamesine Alzheimer Trial

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3124886/29248/en/Anavex-Life-Sciences-Announces-Positive-Precision-Medicine-Results-from-up-to-4-Years-of-Oral-Blarcamesine-Treatment-in-Phase-IIb-III-Open-Label-Extension-Trial-in-Early-Alzheimer-.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results
    Anavex Life Sciences Reports Positive 4-Year Blarcamesine Results

    05 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/05/3056284/29248/en/Anavex-Life-Sciences-Announces-Positive-up-to-4-Years-Oral-Blarcamesine-Results-from-Phase-IIb-III-Open-Label-Extension-Trial-in-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    05 Apr 2025
    Share Share
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015498/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-Blarcamesine-ANAVEX-2-73-Composition-of-Matter-U-S-Patent-Expanding-its-Intellectual-Property-Portfolio.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Anavex's Alzheimer Treatment Result Published In Journal
    Anavex's Alzheimer Treatment Result Published In Journal

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009934/29248/en/Anavex-Life-Sciences-Announces-Peer-Reviewed-Publication-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-The-Journal-of-Prevention-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001118/29248/en/Blarcamesine-Receives-EMA-Filing-Acceptance-for-Treatment-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993663/29248/en/Anavex-Life-Sciences-to-Report-New-Long-Term-Oral-Blarcamesine-Phase-IIb-III-Alzheimer-s-Disease-Data-at-J-P-Morgan-2025-Healthcare-Conference.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share